NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $3,529,000 | +3.9% | 205,708 | +21.2% | 0.23% | -3.3% |
| Q1 2021 | $3,396,000 | +2.9% | 169,777 | -12.5% | 0.24% | -9.0% |
| Q4 2020 | $3,300,000 | +31.1% | 194,116 | +27.9% | 0.27% | +23.1% |
| Q3 2020 | $2,518,000 | -36.2% | 151,761 | -10.9% | 0.22% | -32.1% |
| Q2 2020 | $3,945,000 | +29.3% | 170,321 | -0.3% | 0.32% | +13.2% |
| Q1 2020 | $3,050,000 | -0.6% | 170,823 | +20.2% | 0.28% | +7.7% |
| Q4 2019 | $3,068,000 | +342.1% | 142,090 | +272.6% | 0.26% | +314.3% |
| Q3 2019 | $694,000 | -76.4% | 38,134 | -53.8% | 0.06% | -80.6% |
| Q2 2019 | $2,936,000 | +17.7% | 82,517 | +11.2% | 0.32% | +6.6% |
| Q1 2019 | $2,494,000 | +23.3% | 74,236 | +20.6% | 0.30% | +8.9% |
| Q4 2018 | $2,023,000 | -48.6% | 61,556 | -4.7% | 0.28% | -43.4% |
| Q3 2018 | $3,939,000 | +236.1% | 64,612 | +169.3% | 0.50% | +213.3% |
| Q2 2018 | $1,172,000 | -59.5% | 23,995 | -11.9% | 0.16% | -60.5% |
| Q1 2018 | $2,894,000 | +944.8% | 27,238 | +487.7% | 0.40% | +852.4% |
| Q4 2017 | $277,000 | – | 4,635 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
| MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
| Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
| Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
| Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
| Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
| CM Management, LLC | 35,000 | $595,000 | 0.55% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
| RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
| Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |